Animal and human models for sepsis
Animal and human models for sepsis
复制标题
DOI：
10.1080/078538902321117797
复制
发表时间：
2002-01-01
影响因子：
4.4
通讯作者：
van der Poll, T
中科院分区：
文献类型：
--
作者：
Schultz, MJ;van der Poll, T
在过去的几十年中，已经使用了几种脓毒症的临床前模型来成功地阐明脓毒症期间的病理生理过程。此外，这些脓毒症模型揭示了用于治疗脓毒症的有前景的免疫调节剂。尽管如此。评价这些新抗炎剂在脓毒症患者中的功效的几个临床试验显示出令人失望的结果。本文就脓毒症不同模型的优缺点进行了讨论。大多数脓毒症模型缺乏感染病灶。重要的是，研究几种免疫调节策略的作用的研究表明，当使用缺乏感染病灶的脓毒症模型时，以及当使用具有更自然感染途径的脓毒症模型时，结果惊人地相反。这些差异将在本文中讨论。一般来说，建议在开始评价新疗法的临床研究之前，使用模型组合来测试新的治疗药物。
Several preclinical models for sepsis have been used in the last decades to successfully unravel the pathophysiologic processes during sepsis. Furthermore, these models for sepsis revealed promising immunomodulating agents for the treatment of sepsis. Nevertheless. several clinical trials evaluating the efficacy of these new anti-inflammatory agents in septic patients showed disappointing results. In this article the advantages and disadvantages of different models for sepsis are discussed. Most models for sepsis lack an infectious focus. Importantly, investigations studying the effects of several immunomodulating strategies have demonstrated strikingly opposite results when using models for sepsis lacking an infectious focus and when using models for sepsis with a more natural route of infection. These differences will be discussed in this article. In general, it is advised to use a combination of models to test a new therapeutic agent, before starting a clinical study evaluating this new therapy.